HealthEconomics.Com

Connected. Community.

  • facebook
  • linkedin
  • twitter
  • vimeo
  • rss
  • News
  • Jobs
    • HE Jobs Portal
    • View all Jobs
    • Post a Job
  • The HEOR & RWE Marketplace
    • Visit the Market Place
    • On-demand Webinar
  • Industry Events
    • HealthEconomics.Com Webinars
    • View Conferences
    • View Webinars
  • Newsletters
    • Subscribe
    • View All
  • Blog
  • Resources
    • Value Communication
    • Free Marketing Consultation!
    • The Future of Print Medical Journals: How to Stay Relevant
    • Be a Better Writer
    • White Papers
    • Education Resources
    • Syndicated Reports
    • Books
    • Databases
    • Blogs
      • HE-Artists
      • Podcasts
  • HE Institute
You are here: Home / Featured / When it Comes to COVID-19 Research, The US Still Has A lot to Learn

When it Comes to COVID-19 Research, The US Still Has A lot to Learn

The US is thought to have the most talented scientists along with the best biomedical research infrastructure in the world. However, you wouldn’t know it by looking at the dismal scenario painted by the more than six million coronavirus cases and 183,000 deaths. Surprisingly, the US has produced little in the way of clinical research that has a meaningful impact on preventing infections, hospitalizations, and deaths. Even the remdesivir study, one of the one of the most important in the US to date, did not show a statistically significant reduction in mortality due to an insufficient sample size.

In contrast, Britain has made substantial progress on therapeutics research where the goal is to rapidly conduct large, simple, randomized trials to define standard treatment. In mid-March the NHS began a randomized evaluation of Covid-19 therapies, known as Recovery, involving every hospital in the nation.

The US has an abundance of talented researchers. But unlike Britain, it lacks a clear, unified message from government and other major healthcare stakeholders to put in place large, simple randomized trials that are considered the standard of care for Covid-19 treatment. Read the full story here.

(Source: Ezekiel J. Emanuel, New York Times, September 1, 2020)



You might also be interested in:

  • Study Finds Remdesivir Does Little to Prevent COVID-19 Deaths 11/05/2020
  • Addressing the Affordability Crisis of Cell & Gene Therapies 12/16/2020
  • Robert Dubois, MD, PhD, Steps in as Interim President and CEO… 09/01/2020
  • State Treasurers Call Out Gilead for Putting Remdesivir… 09/21/2020
  • Huge Disconnect Between Dollars Spent On U.S. Healthcare And… 11/10/2020
  • Trump's "Buy American" Executive Order Could Raise Drug Prices 08/06/2020
  • Key Innovations Coming From The Next Generation of PBM’s 08/12/2020

 

View All JobsPost a JobView Current NewsletterSubscribe to Newsletters
Conference of the Week:

Link of the Week:

Job of the Week:

Webinar of the Week:

White Papers

  • Whitepaper: The Role of Centralized Care Management in Value-based Care
  • 2017 In-Depth Outlook on Oncology Report
  • Value-Based Healthcare: Making it Happen
  • Value-Based Contracting for Biopharmaceuticals Moves Forward
  • ICER Releases White Paper on Gene Therapy

Syndicated Reports

  • HTA in Europe: Key Success Factors for Positive HTA Recommendations
  • Paying for Digital Health: Payer Insights
  • Benchmarking Pharma’s MSL Capabilities
  • Biosimilars: US Payer Perspectives
  • KAM Metrics: Driving Efficiency, Measuring Success
HealthEconomics.Com

HealthEconomics.Com

  • News
  • Conferences
  • Reports
  • Jobs
  • Consulting
  • Newsletters
  • White Papers

More Links

  • Jobs
  • Education
  • Graduate Schools
  • Webinar Services

Support & Contact

  • Contact Us

About

  • About Us
  • Advertise
  • Webinar Services
  • HE Institute
  • Testimonials
  • Privacy Policy

Stay Connected

  • facebook
  • twitter
  • linkedin
  • pinterest
  • google-plus
  • youtube
  • rss

HealthEconomics.Com is the world’s most comprehensive and credible CONNECTED COMMUNITYTM that serves as the global link to the health economics & outcomes research (HEOR) and pharma market access stakeholder communities.

HEALTHECONOMICS HZ SMALL V2

HE Institute

Strategy, Training, Education, and Communications in HEOR & Market Access.

Innovation Webinar

Big ideas accelerating change in HEOR, RWE and Health Technology. Learn more!

tHEORetically Speaking Blog

Insights and observations for HEOR, market access, pricing, reimbursement, and health policy.

HE Jobs Portal

Your Premier Employment Source for HEOR, Market Access, and Real World Evidence

HE Webinars

Online educational and informational seminars for HEOR, market access, pricing, and reimbursement.
  • HealthEconomics.Com
  • About HealthEconomics.Com
  • Advertising Inquiries
  • Careers
  • Contact HealthEconomics.Com

HealthEconomics.Com is the world’s most comprehensive and credible CONNECTED COMMUNITYTM that serves as the global link to the health economics & outcomes research (HEOR) and pharma market access stakeholder communities, proving news, education, jobs, resources, policy updates, consulting, advertising, all available via website, newsletters, and social media.

© 2017 Health Economics. All rights reserved.

  • News
  • Jobs
    • HE Jobs Portal
    • View all Jobs
    • Post a Job
  • The HEOR & RWE Marketplace
    • Visit the Market Place
    • On-demand Webinar
  • Industry Events
    • HealthEconomics.Com Webinars
    • View Conferences
    • View Webinars
  • Newsletters
    • Subscribe
    • View All
  • Blog
  • Resources
    • Value Communication
    • Free Marketing Consultation!
    • The Future of Print Medical Journals: How to Stay Relevant
    • Be a Better Writer
    • White Papers
    • Education Resources
    • Syndicated Reports
    • Books
    • Databases
    • Blogs
      • HE-Artists
      • Podcasts
  • HE Institute